Skip to main content


Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Fig. 1 | Breast Cancer Research

Fig. 1

From: Establishing and characterizing patient-derived xenografts using pre-chemotherapy percutaneous biopsy and post-chemotherapy surgical samples from a prospective neoadjuvant breast cancer study

Fig. 1

Comparisons of histological and biomarker characteristics of PDX and their corresponding original patient tumors. Four representative passage 2 PDX models with different clinical subtypes based on ER, PR, and HER2 status, and their corresponding patient tumors are shown. The histology was verified using H&E staining and the expression of ER, PR, HER2, and Ki-67 was visualized using immunohistochemistry. Xenograft tumors are shown in the background with their corresponding human tumors shown in the bottom right inserts. (Scale bar, 50 μm). ER estrogen receptor, H&E hematoxylin and eosin, HER2 human epidermal growth factor receptor 2, PR progesterone receptor

Back to article page